LB0009 ALLOGENIC CD19 CAR NK CELL THERAPY IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS-A CASE SERIES STUDY

医学 耐火材料(行星科学) 免疫学 贝里穆马布 CD19 红斑狼疮 系统性红斑狼疮 B细胞激活因子 内科学 B细胞 抗体 疾病 天体生物学 物理
作者
Ji Gao,Ye Yu,Rui Kong,Xiaojia Xu,Shuwen Liu,Qian Chen,Xiangwen Li,Y. Wu,En Xu,Min Sun,Jilong Yang,Man Li,Dongbao Zhao
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84: 321-321 被引量:4
标识
DOI:10.1016/j.ard.2025.05.396
摘要

Abstract

Background:

Lately, autologus CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent efficacy in treatment of autoimmune diseases, but with great safety concerns, such as infections. In this study, we aimed to evaluate the safety, tolerability and efficacy of allogeneic CD19 CAR-NK cell therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE).

Objectives:

To evaluate the safety and efficacy of allogenic CD19-targeting CAR-nature killing (NK) cells in 18 patients with severe and refractory SLE.

Methods:

In this open-label, single arm, prospective and first-in-human trial, we evaluated allogeneic CD19 CAR-NK cell therapy in adult patients with relapsed or refractory SLE. Patients who had received at least two previous standard systemic therapies and continued to exhibit moderate-to-severe disease activity were eligible for inclusion. This study consisted of schedule- and dose-escalation. All subjects received one 3 doses treatment cycle consisted of 3 doses after conditioning chemotherapy with fludarabine (25 mg/m²) and cyclophosphamide (300 mg/m²) intravenously on days –5 to –3. Dose-limiting adverse events were monitored in patients for 28 days. The primary endpoints of this study were safety and tolerability, including the incidence of dose-limiting toxicities and severe adverse events (SAE) according to National Cancer Institute Common Toxicity Criteria and Adverse Events version 5·0. The secondary endpoint was the efficacy assessed by Physician Global Assessment, SLEDAI-2000 score, definition of low disease activity state (LLDAS) and definition of remission in SLE (DORIS 2021). This trial was registered with ClinicalTrials.gov, NCT06010472.

Results:

26 relapsed or refractory SLE patients with moderate-to-severe disease activity were enrolled. Of the 24 patients, 22 (82%) were female; the median age was 38 years, and the median disease duration was 8.5 years. Patients had received at least two standard systemic therapies, including 18 (75%) of 24 patients treated with biological agents (Belimumab and Telitacicept), and 1 who underwent plasmapheresis. The maximum tolerated dose was not reached. Cytokine release syndrome (CRS) was reported in 2 (8%) (grade 1) of 18 patients, neurotoxicity and other CAR-NK therapy related severe adverse events were not observed. Of the 12 patients with more than 12 months follow-up, 66.7 % (8/12) achieved DORIS remission and 75 % (9/12) achieved LLDAS.

Conclusion:

This study supports that Allogeneic CAR-NK cell therapy is a potent option for autoimmune diseases treatment and indicates that such a therapy might address limitations of currently autologous CAR-T cell therapy, including manufacturing scale and time, access, safety and cost.

REFERENCES:

[1] Muller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med 2024; 390(8): 687-700. [2] Mackensen A, Muller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022; 28(10): 2124-32. [3] Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis 2024.

Acknowledgements:

NIL.

Disclosure of Interests:

Jie Gao: None declared, Yiyi Yu: None declared, Ruina Kong: None declared, Xia Xu: None declared, Suxuan Liu: None declared, Qian Chen: None declared, Xiaofang Li: None declared, Yang Wu I am employed by Rui Therapeutics, Enshun Xu I am employed by Rui Therapeutics, Ming Sun Employed by Rui Therapeutics, Jianmin Yang: None declared, Mengtao Li: None declared, Dongbao Zhao: None declared. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
MMMMathilda23发布了新的文献求助10
刚刚
天天向上的应助被懒洋洋采纳,获得10
刚刚
lll完成签到,获得积分10
刚刚
L912294993完成签到,获得积分10
1秒前
Zwj发布了新的文献求助10
1秒前
2秒前
haha完成签到,获得积分10
2秒前
在水一方的应助被酷酷柚子采纳,获得10
3秒前
莫笑完成签到,获得积分10
3秒前
start完成签到,获得积分10
3秒前
孤独的鸟完成签到,获得积分10
3秒前
袁志阳发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
Crazy_Runner发布了新的文献求助10
4秒前
852的应助被楚楚爸采纳,获得10
4秒前
4秒前
奶黄包完成签到,获得积分10
5秒前
淼淼完成签到,获得积分10
5秒前
5秒前
leo发布了新的文献求助10
5秒前
所所的应助被曾经凌萱采纳,获得10
5秒前
陈梓佳发布了新的文献求助10
5秒前
stoneff发布了新的文献求助10
6秒前
melisa发布了新的文献求助10
7秒前
8秒前
小马甲的应助被江上浩月采纳,获得10
8秒前
潇洒完成签到,获得积分10
8秒前
Utopia完成签到,获得积分10
8秒前
流星发布了新的文献求助10
8秒前
田様的应助被稳重的大侠采纳,获得10
9秒前
淼淼发布了新的文献求助10
9秒前
9秒前
zzzzzzzzy完成签到,获得积分10
10秒前
科研通AI2S的应助被袁志阳采纳,获得10
10秒前
Crazy_Runner完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178280
求助须知:如何正确求助?哪些是违规求助? 9569046
关于积分的说明 21802436
捐赠科研通 7773138
什么是DOI,文献DOI怎么找? 3432735
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478274